Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio Inc. showcases a promising financial outlook, primarily driven by its advanced pipeline featuring innovative oncology therapies, including NUV-868 and Safusidenib, which demonstrate enhanced efficacy and tolerability. The anticipated FDA approval and inclusion into NCCN guidelines for Ibtrozi in 2025 could unlock significant revenue potential in an underserved market valued at over $3 billion. Additionally, the company's drug-drug conjugate platform is designed to improve targeting and minimize toxicity, potentially positioning Nuvation Bio in a favorable competitive stance amid rising demand for effective oncology treatments.

Bears say

Nuvation Bio Inc faces significant challenges that contribute to a negative outlook on its stock. The company's key product candidate, taletrectinib, risks underperforming commercially due to heightened competition and negative clinical proof-of-concept outcomes, which may further hinder the successful advancement of its pipeline programs. Additionally, the possibility of long-term dilution risk, coupled with potential difficulties in securing partnerships for development and commercialization, raises concerns about the company's strategic direction and financial viability.

Nuvation Bio (NUVB) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 10 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.